Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

July 2018

Sarilumab para Pacientes Previamente Tratados con Artritis Reumatoide Moderada o Grave: La Perspectiva de un Grupo de Revisión de Evidencia de Evaluación de Tecnología Única de Nice

Pharmacoeconomics. 2018 Dec;36(12):1427-1437. doi: 10.1007/s40273-018-0677-7

Ren S,

Young A,

In this National Institute for Health and Care (NICE) single technology appraisal of sarilumab (SAR) monotherapy and combination therapy with methotrexate (MTX), SAR was considered to have similar efficacy to other bDMARDs for treating moderate-to-severe RA with inadequate response to cDMARDs or TNFis. SAR was also considered a cost-effective use of National Health Service (NHS) resources versus some or all of its comparators in most considered populations.NICE is an independent organisation res...

April 2018

Baricitinib para Artritis Reumatoide moderada o grave previamente tratada: Una perspectiva de un Grupo de Revisión de Evidencia de una Evaluación de Tecnología

Pharmacoeconomics 2018 Jul; 36(7):769–78

Ren S,

Wong R,

Young A,

In this National Institute for Health and Care (NICE) single technology appraisal of baricitinib (BARI) monotherapy and combination therapy with methotrexate (MTX), BARI efficacy was considered comparable to bDMARDs and a cost-effective use of National Health Service (NHS) resources.NICE is an independent organisation responsible for providing national guidance on health technologies in England. To be recommended by NICE, the company must provide evidence to prove BARI’s effectiveness, both clin...

Keywords:

Tofacitinib para el Tratamiento de Artritis Reumatoide después de Falla a Fármacos Antirreumáticos Modificadores de la Enfermedad: Una Perspectiva de un Grupo de Revisión de Evidencia de una Evaluación de Tecnología Única de NICE

Pharmacoeconomics 2018 Sep; 36(9): 1063–72

Wong R,

Young A,

In this National Institute for Health and Care (NICE) single technology appraisal of tofacitinib (TOF) plus methotrexate (MTX), TOF had similar efficacy and comparable costs to recommended bDMARDs plus MTX in patients with RA. NICE is an independent organisation responsible for providing national guidance on health technologies in England. To be recommended by NICE, the company must provide evidence to prove TOF’s effectiveness, both clinically and costly. This evidence based review, reports the...